January 29, 2024 (Korea Bizwire) Delivers strong sales growth, improved profitability, and strong cash flow in 2023 through solid execution of first year of 2023-2025 plan Agrees with FDA on terms of consent decree focused on Philips Respironics in the US, providing clarity and a roadmap to demonstrate compliance and to restore the business [...]
RIYADH, Saudi Arabia, Jan. 24, 2024 (Korea Bizwire) – King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University’s prestigious list, marking them among the ‘top 2% most-cited scientists’ list updated in October 2023. The recent release recognizes 25 distinguished KFSH&RC scientists, among the top 2% most-cited researchers worldwide in 2021-2022, [...]
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (Korea Bizwire) – Abpro Corporation (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB), a special purpose acquisition company (“Atlantic Coastal”), today announced the filing of [...]
London, Jan. 22, 2024 (Korea Bizwire) – January 22, 2024, London, UK – OPEN Health is pleased to announce the appointment of Steven Duryee as Chief Operating and Transformation Officer. In this role, Steve will be responsible for the execution of the strategic plan, large-scale transformation initiatives, driving growth in the US, and evolving OPEN Health’s go-to-market [...]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US [...]
SHANGHAI, China, Jan. 17, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the publication of results from the prespecified interim analysis for event-free survival (EFS) in patients with stage III non-Small Cell [...]
Mont-Saint-Guibert, Belgium, Jan. 17 (Korea Bizwire) – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor meetings, its strategic priorities for 2024. 2024 Strategic Priorities Complete patient follow [...]
Innovative process solution provider Single Use Support continues to deliver strong organic growth, supported by an expansion in its employee base. With a successful year 2023 in the rear-view mirror, 2024 is already shaping up to be even better. KUFSTEIN, Austria, Jan. 16, 2024 (Korea Bizwire) – Single Use Support has established the groundwork for [...]
Ingelheim am Rhein, Germany, Jan. 11 (Korea Bizwire) – Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, [...]
SHANGHAI, China, Jan. 9 (Korea Bizwire) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced the publication of results from TORCHLIGHT (NCT04085276), a randomized, double-blind, placebo-controlled phase 3 study comparing the efficacy and safety of toripalimab [...]